ADALIMUMAB
adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes
ADALIMUMAB (5283C)
5283C
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: First continuing treatment
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Balance of supply - Continuing treatment
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Subsequent continuing treatment
